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Abstract Basal cell carcinoma of the skin (BCC) is the
most common skin tumor in Caucasians worldwide. DiVer-
ent therapeutic options are available to treat BCC, includ-
ing topical immunotherapy. Imiquimod is topical Toll-like
receptor 7 agonist that activates anti-tumor immune
response and has been recently approved for the treatment
of superWcial BCC (sBCC). We sought to investigate the
inXuence of imiquimod treatment on the members of the
Notch signaling pathway, whose activity is known to be
decreased in BCCs. Six patients with sBCC were evaluated
for Notch1, Jagged1 and Delta1 expression before (pre-
treatment) and after the beginning of the topical treatment
(post-treatment) with imiquimod using real-time PCR and
immunohistochemistry. We show selective transcriptional
up-regulation of Notch pathway members (Notch1, Jag-
ged1 and Delta1) in tumor cells of the sBCC post-treat-
ment. Furthermore, we demonstrate minor increase of
Notch1 protein expression on inWltrating cells as well as
strong increase in Jagged1 protein expression in regressing
sBCC tumors post-treatment. In this way, imiquimod may
act as a stimulator of the Notch pathway in sBCC tumor
cells by up-regulating protein expression of the Notch
ligand, Jagged1. Via induction of Notch signaling imiqui-
mod may exert tumor suppressor function, which together
with its proinXammatory properties results in tumor regres-
sion.
Keywords Basal cell carcinoma · Imiquimod · Notch1 · 
Jagged1 · Delta1
Introduction
Basal cell carcinoma (BCC) is the most frequent malignant
skin tumor in the white human population worldwide and it
accounts for about 75% of all skin cancers [23]. BCC
belongs to non-melanoma skin cancers, like squamous cell
carcinoma of the skin [21, 23]. Its incidence has increased in
the last decade, due to the sun exposure and increased life
expectancy. To date, the pathogenesis of BCC is not fully
elucidated. Even though the role of activated Hedgehog
pathway in BCC development has been established in
numerous studies, other pathways seem to be of equal
importance, such as Notch-signaling pathway [6]. There is
circumstantial evidence that BCCs originate from the basal
layer of the outer root sheath of the hair follicle [9], which
closely resembles the interfollicular basal layer of the epi-
dermis with respect to protein expression patterns, including
Notch [14]. Notch cell-to-cell signaling promotes diVerenti-
ation of epidermal stem cells [4, 11, 12]. Notch and its
ligands, Delta and Jagged, play an important role in devel-
opment of normal epithelial tissue and maintaining homeo-
stasis [12]. Notch members are involved in the control of
cell fate determination and diVerentiation of epithelial stem
cells. Notch signaling is not only involved in the develop-
ment of normal epithelial tissues, but it also seems to play a
role in tumorigenesis [20]. Dysregulation of Notch signaling
pathway has been observed in diVerent cancers, most which
originate from epithelial structures [1]. In contrast to other
organs, Notch1 appears to act as a tumor suppressor in the
skin [11, 15]. Ablation of Notch1 from epidermal cells in
mice leads to an uncontrolled proliferation of the basal epi-
dermal layer and results in BCC-like tumors [15].
The newly registered drug for the external treatment of
superWcial BCCs (sBCC) is a topical immune response
modiWer named imiquimod (marketed as 5% cream,
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Aldara®) [24, 25]. Imiquimod is a small synthetic com-
pound that activates Toll-like-receptor 7 (TLR-7), which is
expressed on plasmacytoid dendritic cells, macrophages
and monocytes. This results in an increased production of
inXammatory cytokines, such as interferon- and potent
stimulation of anti-tumor immunity that eventually leads to
tumor destruction [24, 25].
In this study, we sought to investigate changes in Notch
signaling pathway in patients, whose sBCC were treated
with imiquimod. We show transcriptional up-regulation of
Notch pathway members (Notch1, Jagged1 and Delta1). In
addition, we demonstrate minor increase in Notch1 as well
as strong increase in Jagged1 protein expression in regress-
ing sBCCs treated with imiquimod.
Materials and methods 
Patients
The analyses performed herein utilized the material from
six patients with sBCC participating in two clinical open-
label studies that investigated the changes in the inXamma-
tory inWltrate in sBCC treated with a 5% imiquimod cream
(Aldara, 3M Pharmaceuticals, St Paul, MN). Both studies
were approved by the Institutional Ethics Committee.
Before entering either study, patients provided written
informed consent. At the screening visit that took place
2 weeks before treatment initiation, a biopsy specimen was
taken for histologic conWrmation of sBCC (pre-treatment
samples). Patients applied imiquimod to the target sBCC
lesion once daily until the treated tumor showed signs of
erosion (generally after 3–5 days), which was then fol-
lowed by complete excision of the tumor (post-treatment
samples). Every pre- and post-treatment tissue sample was
divided in two, one half was immediately snap frozen and
stored at ¡80°C, whereas the other half was Wxed in forma-
lin and subsequently embedded in paraYn.
Real-time quantitative PCR
Total RNA was extracted from frozen tissue samples using
TRIzol reagent (Invitrogen AG, Basel, Switzerland)
according to the manufacturer’s recommendations.
Approximately, 1 g of total RNA was reverse transcribed
using Wrst Strand cDNA Synthesis Kit for RT-PCR (Roche
Diagnostics, Rotkreuz, Switzerland) at 42°C for 90 min.
PCR ampliWcations were carried out with the HotStart sys-
tem (LightCycler-Faststart DNA Master SYBR Green I,
Roche Diagnostics) in the LightCycler thermocycler
(Roche Diagnostics). Primer sets for PTCH, GAPDH,
Notch1, DELTA1 and JAGGED1 were purchased from
Search LC (GmbH, Dossenheim, Germany).
Immunohistochemical analysis
ParaYn-embedded tissue sections were stained with the
following primary antibodies: anti-Notch1 (clone A6,
mouse IgG2b, Acris Antibodies GmbH, Hiddenhausen,
Germany) and anti-Jagged1 (clone c-20, polyclonal goat
IgG, Santa Cruz Biotechnology Inc., Santa Cruz, CA).
After antigen retrieval, immunohistochemistry was per-
formed using alkaline phosphatase–anti-alkaline phospha-
tase technique, as previously described [25].
Results
Real-time PCR reveals selective up-regulation of Notch 
pathway members upon imiquimod treatment
To assess early changes in sBCC responding to topical
imiquimod treatment, we analyzed gene expression levels
of Notch1, DELTA1 and JAGGED1 gene in six patients by
real-time quantitative PCR. Knowing that GAPDH gene is
expressed by all cell types present in analyzed biopsies, we
Wrst analyzed the expression of above-mentioned genes
normalized to GAPDH expression. Notch1 gene levels
were up-regulated in one patient (patient 4; Fig. 1a). JAG-
GED1 gene expression levels remained unchanged during
imiquimod treatment. DELTA1 mRNA expression was
slightly increased in three patients (patients 2, 4 and 5).
Next, we focused on the transcriptional changes in tumor
cells and used normalization to patched (PTCH) gene
instead of GAPDH. All patients demonstrated a decrease in
overall PTCH expression 3–5 days after imiquimod treat-
ment (Fig. 1b) reXecting the ongoing tumor regression, i.e.
reduction of the viable tumor tissue. After normalization to
PTCH, we could observe increase of Notch1 expression
post-treatment in all patients (Fig. 1c). Two patients
showed a strong up-regulation of Notch1 by 118-fold
(patient 1) and 310-fold (patient 4) in post-treatment biop-
sies as compared to pre-treatment samples. JAGGED1
mRNA levels were similarly increased in all patients after
topical application of imiquimod. Patient 1 showed again a
strong increase of 150-fold in JAGGED1 mRNA levels.
DELTA1 gene expression was increased in patients 1–5
after treatment with imiquimod. Patient 1 presented once
again with high up-regulation of Delta1 as compared to
other patients.
To evaluate changes in expression levels of Notch1,
JAGGED1 and DELTA1 in the inWltrate, we also used nor-
malization to CD4 gene. An increase in CD4 cell popula-
tion has been described as an early event in the Wrst week of
the imiquimod treatment [3, 26]. Three out of six patients
(patients 2, 3 and 6) in our current study showed increased
relative CD4 mRNA levels post-treatment (Fig. 1b). With
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respect to CD4, Notch1, JAGGED1 and DELTA1 gene up-
regulation occurred in patients 1 and 4, whereas patient 5
also showed a slight increase in DELTA1 gene expression
(Fig. 1d).
Our results show that imiquimod treatment induces
selective and heterogeneous transcriptional up-regulation
of Notch pathway members in treated lesions.
Jagged1 protein and not Notch1 is primarily up-regulated 
in imiquimod treated tumors
To further study the eVect of imiquimod on Notch pathway
in BCCs, we carried out immunohistochemical stainings on
the paraYn-embedded tumor tissue samples using antibod-
ies against Noch1 and Jagged1 (Table 1). As expected,
Notch1 protein was expressed to the granular layer of the
tumor-surrounding epidermis in all evaluated patients.
Tumor cells were generally negative for Notch1 protein
expression pre- and post-treatment, which contrasted the
real-time PCR results (Figs. 1a, c, d, 2a). Only one patient
(patient 6) demonstrated increased immunoreactivity of the
tumor cells to Notch1 after therapy with imiquimod with
partially matching PCR data (Fig. 2a). While looking for
other cell types expressing Notch1 receptor, we found an
increase in Notch1 protein expression on inWltrating
immune cells in Wve patients (patients 1–4 and 6) post-
treatment, which was corresponding to PCR data only in
patients 1, 4 and 5 (Figs. 1d , 2a).
Low levels of Jagged1 expression were detected in the
surrounding epidermis of the four patients (patients 2–5),
with patient 6 expressing somewhat more Jagged1 intraepi-
dermally. Jagged1 expression was conWned to basal cell layer
and did not seem to change upon imiquimod treatment.
Serial cuts of paraYn-embedded tumors resulted in the lack of
tumor tissue on the slides used to assess Jagged1 expression
in patients 1 and 5. Only four patients were, therefore, evalu-
able for changes in the tumor post-treatment. At pre-treat-
ment, tumor cells displayed diVerent levels of Jagged1
Fig. 1 Gene expression of 
Notch1, Jagged1 and Delta1 in 
sBCC before and after topical 
therapy with imiquimod (a, c 
and d). For each sample, mRNA 
expression of the target gene was 
normalized to mRNA expression 
of the GAPDH (a), PTCH (c) 
and CD4 (d) gene and shown as 
a ratio (e.g. Notch1 copy number 
per l/Ptch copy number per l ). 
Bars represent fold change in-
crease in post-treatment versus 
pre-treatment samples. c and d 
contain additional information 
of protein levels of the respec-
tive gene product assessed by 
immunohistochemistry (IHC) 
(triangle stands for up-regula-
tion; equal to stands for no 
change). b shows relative 
expression of PTCH and CD4 
genes normalized to GAPDH
Table 1 Immunohistochemical analysis of Notch1 and Jagged1
expression in sBCCs treated with imiquimod
Expression is graded as: (¡) no expression, (§) single cell expression,
(+) expression in less than 40% of inWltrate, (++) expression in more
than 80% of inWltrate. 0, pre-treatment; IM, post-treatment; no tumor,
no evidence of tumor on the post-treatment slide
Patients Notch1 Jagged1
Epidermis Tumor InWltrate Epidermis Tumor InWltrate
P1 0 Always 
positive 
to granular 
layer
¡ ¡ ¡ ++ Always 
negativeP1 IM ¡ § No tumor
P2 0 ¡ § ¡ ¡
P2 IM ¡ + § ++
P3 0 ¡ ¡ § +
P3 IM ¡ + § +
P4 0 ¡ ¡ § ¡
P4 IM ¡ § § ++
P5 0 ¡ § § +
P5 IM ¡ § No tumor
P6 0 ¡ ¡ + +
P6 IM + + + ++
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expression ranging from lack of (Fig. 2b) to true protein
expression. In contrast to Notch1 protein expression, Jag-
ged1 protein was strongly induced in tumors of three
patients (patients 2, 4 and 6) upon imiquimod treatment
(Fig. 2c). InWltrating immune cells stayed negative for Jag-
ged1 protein expression irrespective of the treatment. Jag-
ged1 protein expression correlated with PCR data only
partially (Fig. 1a, c, d). Taken together, imiquimod seems
to preferentially induce protein expression of the Notch
ligand, Jagged1 rather than the expression of Notch1 recep-
tor itself in treated tumors.
Discussion
The Notch system was Wrst described as being responsible
for neurogenesis and ectodermal speciWcation in Drosoph-
ila [2]. In mammals, there are four evolutionary conserved
Notch receptors (Notch1–4) that are activated by Wve
canonical Notch ligands Jagged1 and 2, Delta-like 1, 3 and
4. Notch signaling controls the development of most tissues
by inXuencing cell death, proliferation and fate speciWca-
tion through cell–cell communication [2, 10]. Notch acts a
control of the developmental processes though binary deci-
sion, lateral inhibition and boundary formation [12, 25].
The essential characteristic of Notch-mediated cell commu-
nication depends on diVerential expression of ligand and
receptor on the cell surface [2, 4, 8, 10]. The cells stimulate
each other to produce high levels of ligands and this again
results in high receptor activation. High levels of ligand
expression with subsequent Notch activation causes cell
diVerentiation (and arrests the cell growth) and hence con-
trols the cluster size. Notch plays an important role in the
development and organization of diVerent healthy tissues,
but it also plays a role in tumorgenesis [1, 20]. Notch sig-
naling is decreased in uncontrolled proliferating conditions,
such as psoriasis [22]. Impaired Notch is also described to
promote the development of squamous cell carcinoma of
the skin and melanoma [13, 18]. Conversely, Delta/Notch
signaling is increased in cells that undergo normal diVeren-
tiation program, as in cell layers of the normal adult human
epidermis [22]. Manipulation of Notch signaling could be
therefore advantageous for the treatment of cancer. How-
ever, the function and the regulation of the Notch family
members in the control of human skin tumors are not yet
fully understood. In the skin, Notch seems to function as a
tumor suppressor, as shown by Nicolas et al. [4, 15]. Loss
of Notch1 in young mice induces hyperproliferation of the
basal epidermal layer and deregulates expression of multi-
ple diVerentiation markers, p21 is decreased and Gli2 is
overexpressed [15]. Tumors that spontaneously develop in
mice lacking Notch1 display BCC-like phenotype.
Expression of Notch1 and its ligands varies in the diVer-
ent layers of the epidermis [22]. In the healthy skin Notch1,
Delta1 and Jagged1 are detectable in the whole epidermis,
with pronounced expression of the latter two in the basal
layer. Thélu and coworkers examined BCCs and found that
the protein expression of Notch receptor and the ligands,
Delta1 and Jagged1 was severely lowered in tumor regions
[22]. They also observed expression of neither of the pro-
teins in the regions with pallisading cells penetrating the
dermis. In absence of Notch1, Delta1 and Jagged1 missing
or decreased Notch signaling leads to disorder in epidermal
diVerentiation and proliferation [22]. Our data demonstrate
that Jagged1 protein is preferentially up-regulated follow-
ing treatment with imiquimod. Jagged1 plays an important
role in the diVerentiation of keratinocytes, as the activation
of Notch pathway triggers terminal keratinocytes diVerenti-
ation [4, 11, 12, 14]. As mentioned above, in BCCs the
expression of Notch receptor and ligand is decreased in
tumor regions [22]. When keratinocytes enter a pathological
Fig. 2 Immunohistochemistry of Notch1 and Jagged1 protein in
sBCC before (b) and after topical therapy with imiquimod (a) and (c),
respectively. Original magniWcation was £10
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status, they neither transcribe ligands nor receptor and thus
the diVerentiating signal is absent [4, 22]. Our study shows
that immunomodulatory treatment with imiquimod selec-
tively up-regulates gene expression of Notch receptors
(Notch1) and ligands (Jagged1, Delta1) in treated tumors.
The results of the normalization to PTCH gene should be,
however, interpreted with caution. Reduction of the viable
tumor tissue may result in an artiWcially increased gene/
PTCH ratio and would correspond, e.g. to the observed lack
of Notch1 protein expression on tumor cells. Nevertheless,
post-transcriptional modiWcations leading to discrepancy
between RNA and protein levels cannot be excluded, as
there are no currently available functional data on Notch1
regulation following TLR triggering. This eVect of imiqui-
mod on the skin seems to be rather drug and not disease-
speciWc, since Jacobs et al. reported expression of
NOTCH2 and 4 in the skin and common viral warts, but
failed to detect their up-regulation after imiquimod treat-
ment [7]. On the other hand, up-regulation of the ligand
protein (Jagged1) would provide the missing signal for
inducing diVerentiation and could theoretically inXuence
the tumor phenotype [19]. So it seems that treatment with
imiquimod has the potential to overcome BCC’s biology
and to stimulate the Notch pathway through the up-regula-
tion of the Nocht-ligand Jagged1.
Imiquimod is a potent immune response modiWer that
activates TLR7, which results in an activation of NF-B [5]
and increased production of proinXammatory cytokines and
a potent stimulation of anti-tumor Th1 immunity [24, 25].
Treatment with imiquimod induces massive peritumoral
and intratumoral inWltration. Notch and its ligands play an
important and critical role in cell fate determination of
many cell types, including the lymphoid and dendritic cells
[16, 27]. We observed only rare expression of the ligand
Jagged1 on mononuclear cells in the inWltrate. Apart from
T-cell development, signaling through Notch receptors
appears to regulate the proteins that are crucial for periphe-
ral T-cell activation and diVerentiation, such as NF-B and
IFN- [17]. Jagged1 is implicated to be a downstream target
of NF-B activation providing the loop between these two
pathways [17]. Given the putative intersection of Notch and
NF-B signaling, it is conceivable that by activating TLR-7
imiquimod activates other downstream pathways in
immune cells that enable mounting of an eYcient immune
response and tumor elimination.
In conclusion, our present study describes that imiqui-
mod stimulates expression of Jagged1 protein in sBCC
tumor cells. Via induction of Notch signaling imiquimod
may exert tumor suppressor function, which together with
its proinXammatory properties results in tumor regression.
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